Loading…
Employees: 276
Size Abbisko Cayman (2256.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $589M, the 720th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$6.36 on 6 Nov 2026.
Performance Over six months the shares fell 48.5%, against -21.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 83.3% over the last twelve months (peer median +2.6%); the operating margin is -519.6% (peer median 4.3%).
Valuation It trades at 20.8× enterprise value to sales against a peer median of 5.0× (3rd most expensive of 18).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$111M | HK$664M | HK$546M | HK$21.1M | HK$0 |
| Revenue growth | — | +21% | +2,495% | — | — |
| Gross profit | HK$84.8M | HK$640M | HK$521M | HK$704,989 | -HK$18.4M |
| EBITDA | -HK$552M | HK$54.5M | HK$2.14M | -HK$544M | -HK$560M |
| Net income | -HK$520M | HK$59.9M | HK$30.7M | -HK$477M | -HK$576M |
| Free cash flow | -HK$390M | HK$142M | HK$40.4M | -HK$443M | -HK$399M |
| Capital expenditure | HK$4.70M | HK$6.00M | HK$8.02M | HK$13.5M | HK$26.5M |
| Total debt | n/a | HK$338M | HK$25.8M | HK$39.3M | HK$51.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2256.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.6% | -7.2% | 2nd lowest of 21 |
| 6-month return | -48.5% | -21.4% | 2nd lowest of 21 |
| Distance from 52-week high | -57.9% | -35.8% | 4th lowest of 21 |
| Revenue growth (TTM) | -83.3% | +2.6% | 2nd lowest of 19 |
| Operating margin | -519.6% | 4.3% | 3rd lowest of 18 |
| EV / Sales | 20.8× | 5.0× | 3rd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | 20.8× | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 2.0× | 14.8% | +9.7% |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | 0.8× | 5.0% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 6.4× | 27.9% | +15.8% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 2.9× | -11.1% | +8.8% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 1.4× | -3.2% | +4.1% |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | 62.6× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | 5.0× | 5.5% | -1.1% |
| Bicara Therapeutics BCAX | United States | $572M | -62% | n/a | n/a | n/a | n/a | n/a |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 0.5× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $566M | +25% | +40% | 24% | 7.9× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $566M | -28% | -11% | -8% | 6.5× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 2.2× | -14.3% | +2.8% |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 3.3× | 25.4% | +31.4% |
| Ovid Therapeutics OVID | United States | $557M | +2% | -76% | -3,687% | 285.6× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $553M | -28% | +1% | -28% | 6.8× | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | 7.1× | n/a | n/a |
| Orchid Pharma ORCHPHARMA.NS | India | $551M | +27% | +11% | 0% | 5.5× | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |